CTOs on the Move

Advocate Home Specialty Care

www.advocarehomecare.com

 
Advocate Home Specialty Care is a Wamego, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Orthodontic Design and Production

ODP has developed and evolved constantly over the years to reach its present position as one of the world's premier manufactures of orthodontic appliances and accessories. We have been distributing internationally and domestically since we started and

Optras Systems Pvt.

Optras Systems Pvt. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acupuncture Association

Acupuncture Association is a Longueuil, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mattson Jack Group

Mattson Jack Group is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Saint Louis, MO. To find more information about Mattson Jack Group, please visit www.mattsonjack.com

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.